Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMENICA: Dostarlimab vs chemotherapy in MMR-deficient advanced endometrial cancer
jRCT2031240065Phase 3Active, not recruiting
- Sponsor
- Arcagy-Gineco
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of dostarlimab in endometrial adenocarcinoma (2 arms), sponsored by Arcagy-Gineco. Primary endpoint: Progression-free survival (PFS) by BICR. Started Jun 2024; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on jRCT2031240065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240065.